Loading…
ADC Therapeutics SA is projected to rise to $1.33 by 2027, a +27% move from its current price of $1.05. ADCT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $1.01 | $1.05 | $1.09 | 0.00% |
| Aug 5 | $0.9958 | $1.05 | $1.11 | -0.01% |
| Aug 6 | $0.9839 | $1.05 | $1.12 | -0.01% |
| Aug 7 | $0.9741 | $1.05 | $1.13 | -0.01% |
| Aug 8 | $0.9655 | $1.05 | $1.14 | -0.02% |
| Aug 9 | $0.9578 | $1.05 | $1.15 | -0.02% |
| Aug 10 | $0.9507 | $1.05 | $1.16 | -0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.9507 | $1.05 | $1.16 | -0.02% |
| Week 2 | $0.9123 | $1.05 | $1.21 | -0.04% |
| Week 3 | $0.8838 | $1.05 | $1.25 | -0.07% |
| Week 4 | $0.8605 | $1.05 | $1.28 | -0.09% |
| Week 5 | $0.8404 | $1.05 | $1.31 | -0.11% |
| Week 6 | $0.8226 | $1.05 | $1.34 | -0.13% |
| Week 7 | $0.8066 | $1.05 | $1.36 | -0.16% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Incorporated in 2011 and headquartered in Epalinges, Switzerland, the company operates as a healthcare biotechnology entity focused on ADCs.
Its flagship product includes ZYNLONTA, a CD19-directed ADC, which received accelerated approval from the U.S. FDA, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL), as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs).
Further, the company is investigating a CD-22 targeted compound and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Its pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
ADC Therapeutics SA (ADCT) is a healthcare stock with a current price of $1.05 and a market capitalization of $133.55M, ranked at 4015. The stock sits in the small-cap biotech space within the broader healthcare landscape.
The forecast suggests a long-term bullish trajectory for the name, with year-by-year prices showing growth from 2026 onward. The 2026 forecast centers at an avg of $1.05 with a min of $0.978 and a max of $1.43, and the outlook strengthens through 2027–2050 with rising averages and positive ROI figures. By 2050, the avg is projected at $3.80 with a max of $7.99 and a sizable long-run upside.
A major floor 22.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.9% away) — a key level to hold.
The nearest ceiling, 28.6% above — a clean break opens room to run.
A major ceiling 317.1% above — clearing it would confirm fresh momentum.
Key ADCT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ADCT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.10 | Sell | $1.10 | Sell |
| MA 10 | $1.16 | Sell | $1.15 | Sell |
| MA 20 | $1.23 | Sell | $1.22 | Sell |
| MA 50 | $1.59 | Sell | $1.67 | Sell |
| MA 100 | $2.73 | Sell | $2.32 | Sell |
| MA 200 | $3.34 | Sell | $2.82 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 30.01 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -165.05 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -17.97 | Sell |
| Bollinger %B (20,2) | -0.01 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -1.27 | Sell |
| Awesome (5,34) | -0.06 | Sell |
| Ultimate (7,14,28) | 17.95 | Buy |
| Momentum (10) | -0.30 | Sell |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 1.06 | Sell |
| ADX (14) | 33.25 | Sell |
| ATR (14) | 0.05 | Info |
The 30-day technical picture is neutral with an RSI(14) of 30. Price momentum remains modest and sentiment is NEUTRAL. The stock is currently trading near support around $1.02 and faces resistance near $1.35, with a 30-day price range from $0.8203 to $1.34.
The 50-day simple moving average sits at $1.59, while the 200-day simple moving average sits at $3.34, indicating the near-term price trajectory could be pressured by the longer-term moving-average structure. The stock exhibits notable volatility, with annualized volatility at 70%, underscoring the potential for outsized moves in either direction.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.978 | $1.05 | $1.43 | 0% | Neutral | |
| $1.03 | $1.33 | $1.85 | +27% | Bullish | |
| $1.09 | $1.47 | $2.14 | +40% | Bullish | |
| $0.9217 | $1.29 | $1.95 | +23% | Bullish | |
| $0.9253 | $1.33 | $2.08 | +27% | Bullish | |
| $0.9475 | $1.40 | $2.25 | +34% | Bullish | |
| $0.8558 | $1.30 | $2.14 | +24% | Bullish | |
| $1.05 | $1.64 | $2.76 | +56% | Bullish | |
| $1.20 | $1.91 | $3.27 | +82% | Bullish | |
| $1.17 | $1.91 | $3.33 | +82% | Bullish | |
| $1.36 | $2.46 | $4.63 | +134% | Bullish | |
| $1.74 | $3.80 | $7.99 | +262% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.978 | $1.05 | $1.24 | +0.00% |
| September 2026 | $0.8313 | $0.9937 | $1.23 | -5.36% |
| October 2026 | $0.8675 | $1.05 | $1.31 | +5.35% |
| November 2026 | $0.9111 | $1.11 | $1.41 | +5.85% |
| December 2026 | $0.9091 | $1.11 | $1.43 | +0.49% |
Click any year to see its month-by-month ADCT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, ADCT could reach as high as $1.43, with a base case around $1.05 and support toward $0.978 — roughly 0% from $1.05. A consolidation phase looks the most probable path here.
Expect ADCT to range from $1.03 to $1.85 through 2027. The $1.33 average target implies a +27% move from current prices. That is up +27% on the projected 2026 average. Momentum favours further upside here.
The ADCT price prediction for 2028 points to an average of $1.47 (low $1.09, high $2.14) — a potential gain of +40% on today's $1.05. Buyers look set to stay in control over this stretch.
In 2029, ADCT is projected to trade between $0.9217 and $1.95, averaging $1.29 — a potential gain of +23% from today's $1.05. That is -12% versus the projected 2028 average. Momentum favours further upside here.
ADC Therapeutics SA's 2030 outlook centres on $1.33, within a $0.9253 to $2.08 range. That is up +3% on the projected 2029 average. That marks a +27% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, ADCT could reach as high as $2.25, with a base case around $1.40 and support toward $0.9475 — roughly +34% from $1.05. Momentum favours further upside here.
Expect ADCT to range from $0.8558 to $2.14 through 2032. The $1.30 average target implies a +24% move from current prices. That is -7% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
The ADCT price prediction for 2033 points to an average of $1.64 (low $1.05, high $2.76) — a potential gain of +56% on today's $1.05. Momentum favours further upside here.
In 2034, ADCT is projected to trade between $1.20 and $3.27, averaging $1.91 — a potential gain of +82% from today's $1.05. That is up +16% on the projected 2033 average. Buyers look set to stay in control over this stretch.
ADC Therapeutics SA's 2035 outlook centres on $1.91, within a $1.17 to $3.33 range. That is 0% versus the projected 2034 average. That marks a +82% change versus current levels. Momentum favours further upside here.
By 2040, ADCT could reach as high as $4.63, with a base case around $2.46 and support toward $1.36 — roughly +134% from $1.05. Buyers look set to stay in control over this stretch.
Expect ADCT to range from $1.74 to $7.99 through 2050. The $3.80 average target implies a +262% move from current prices. That is up +55% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ADCT today (≈ 952.380952 ADCT) could be worth
$3,618.18
+$2,618.18 (+262%) by 2050 · US Dollar
Based on the average projected ADCT price of $3.8 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ADCTwould be worth at today's price.
$1,000 invested in ADCT on Jul 31, 2025 (≈ 361.010833 ADCT) would be worth
$379.06
-$620.94 (-62.1%) today · 0.38× · US Dollar
Based on a ADCT entry price of $2.77 vs. today's $1.05.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.15 | $913.04 | -8.7% |
| 1 month ago | $1.14 | $921.05 | -7.9% |
| 3 months ago | $3.83 | $274.15 | -72.6% |
| 6 months ago | $3.9 | $269.23 | -73.1% |
| 1 year ago | $2.77 | $379.06 | -62.1% |
| All time (5.0y) ago | $23.81 | $44.1 | -95.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ADCT forecast.
Our base-case forecast reaches $2.10 around 2040.
Implied market cap at $2.10: $267.1M
Looking across the multi-year forecast, the path is broadly bullish with rising averages and meaningful upside. In 2027 the avg price is $1.33 with a 26.9% ROI and a bullish sentiment, followed by 2028 at $1.47 (40% ROI) and 2029 at $1.29 (22.5% ROI).
The forecast shows continued strength into 2030 at $1.33 avg and 27.1% ROI, 2031 at $1.40 avg with 33.6% ROI, and 2032 at $1.30 avg with 23.6% ROI. By 2033 the avg rises to $1.64 (56.5% ROI), 2034 to $1.91 (82% ROI), and 2035 to $1.91 (81.5% ROI), all with bullish sentiment.
The upside accelerates in later years, with 2040 projecting an avg of $2.46 (134.1% ROI) and 2050 projecting an avg of $3.80 (261.8% ROI). These figures imply substantial long-term appreciation potential, tempered by the usual uncertainties in biotech equity outcomes and regulatory timelines.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $1.33 with a min of $0.9265, a max of $2.08 and a ROI of 27.1%, with a bullish sentiment.
The forecast depicts a bullish long-term path, with rising averages from 2026 onward and a 2050 avg of $3.80 with a 261.8% ROI, though near-term moves vary and risk is inherent in biotech equities.
Yes. The 2030 max is $2.08, the 2040 max is $4.63, and the 2050 max is $7.99, indicating potential higher-price scenarios under the given forecast.
The 30-day picture shows NEUTRAL sentiment with RSI(14) at 30, price near support of $1.02 and resistance at $1.35, and a 30-day range of $0.8203 to $1.34.
Current price is $1.05 and market cap is $133.55M, with rank 4015.
ADC Therapeutics SA Community Discussion
0Share your ADC Therapeutics SA price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.